Effect of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia-lymphoma: Cutaneous adverse reactions may predict the prognosis

Journal of Dermatology

Volumn 41, Issue 3, 2014, Pages 239-244

  Yonekura, Kentaro ^a   Kanzaki, Tamotsu ^a   Gunshin, Kanayo ^a   Kawakami, Nobuyo ^a   Takatsuka, Yoshifusa ^b   Nakano, Nobuaki ^b   Tokunaga, Masahito ^b   Kubota, Ayumu ^b   Takeuchi, Shogo ^b   Kanekura, Takuro ^a   Utsunomiya, Atae ^b  

^a IMAMURA BUN IN HOSPITAL   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

adult T cell leukemia lymphoma; chemokine receptor 4; cutaneous adverse reaction; cytotoxic T lymphocyte; mogamulizumab

Indexed keywords

MOGAMULIZUMAB; CCR4 PROTEIN, HUMAN; CHEMOKINE RECEPTOR CCR4; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BLOOD; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CD25+ T LYMPHOCYTE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; ERYTHEMA; ERYTHRODERMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; INFUSION RELATED REACTION; LEUKEMIA RELAPSE; LYMPH NODE; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; SKIN DEFECT; T CELL LEUKEMIA; TREATMENT RESPONSE; AGED; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DRUG ERUPTIONS; LEUKEMIA-LYMPHOMA, ADULT T-CELL; PATHOLOGY; PROGNOSIS; RECURRENT DISEASE; SKIN;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG ERUPTIONS; FEMALE; HUMANS; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, CCR4; RECURRENCE; SKIN;

EID: 84896380062     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/1346-8138.12419     Document Type: Article

References (8)

1. Iellem A, Mariani M, Lang R, et al,. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exp Med 2001; 194: 847-853.
2. Ishida T, Ishii T, Inagaki A, et al,. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res 2006; 66: 5716-5722.
3. Ishida T, Inagaki H, Utsunomiya A, et al,. CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. Clin Cancer Res 2004; 10: 5494-5500.
4. Tsukasaki K, Utsunomiya A, Fukuda H, et al,. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 2007; 25: 5458-5464.
5. Ishii T, Ishida T, Utsunomiya A, et al,. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. Clin Cancer Res 2010; 16: 1520-1531.
6. Ishida T, Joh T, Uike N, et al,. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol 2012; 30: 837-842.
7. Yamada Y, Tomonaga M, Fukuda H, et al,. A new G-CSF-supported combination chemotherapy, LSG-15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol 2001; 113: 375-382.
8. Ishida T, Ito A, Sato F, et al,. Stevens-Johnson syndrome associated with mogamulizumab treatment of adult T-cell leukemia/lymphoma. Cancer Sci 2013; 104: 647-650.